Scinopharm Taiwan (TPE:1789) Short-Term Debt: NT$170 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1789 Scinopharm Taiwan Ltd TPE:1789
76 GF Score
Price NT$19.05
GF Value NT$25.08
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Short-Term Debt?

Scinopharm Taiwan TPE:1789 -1.80% 76 Short-Term Debt is NT$170 Mil as of Mar. 2026. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$25.08 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Scinopharm Taiwan's Short-Term Debt for the quarter that ended in Mar. 2026 was NT$170 Mil.

Scinopharm Taiwan's quarterly Short-Term Debt declined from Sep. 2025 (NT$139 Mil) to Dec. 2025 (NT$130 Mil) but then increased from Dec. 2025 (NT$130 Mil) to Mar. 2026 (NT$170 Mil).

Scinopharm Taiwan's annual Short-Term Debt increased from Dec. 2023 (NT$33 Mil) to Dec. 2024 (NT$37 Mil) and increased from Dec. 2024 (NT$37 Mil) to Dec. 2025 (NT$130 Mil).

Scinopharm Taiwan Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Scinopharm Taiwan Short-Term Debt Related Terms

Scinopharm Taiwan Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Short-Term Debt Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.17 78.83 33.32 36.77 130.44

Scinopharm Taiwan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.27 82.78 139.48 130.44 170.13
TPE:1789
76GF Score
Scinopharm Taiwan Ltd TPE:1789
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$170 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Short-Term Debt of NT$170 Mil as of Mar. 2026.
Is Scinopharm Taiwan's Short-Term Debt too high?
Scinopharm Taiwan's current Short-Term Debt is NT$170 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Short-Term Debt compare to ZTS?
Scinopharm Taiwan's Short-Term Debt of NT$170 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Scinopharm Taiwan's current Short-Term Debt is NT$170 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$25.08, compared to a current price of NT$19.05 — trading 24% below its estimated fair value. The current Short-Term Debt is NT$170 Mil. Scinopharm Taiwan's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Short-Term Debt is NT$170 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$19.05 is trading 24% below its estimated GF Value™ of NT$25.08. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Short-Term Debt: NT$170 Mil
  • GF Value™: NT$25.08 vs. price of NT$19.05 (24% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score

Get the complete analysis for TPE:1789

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.05
Price
NT$25.08
GF Value